timothy sykes logo
Precigen Shares on the Rise: Is Now the Time to Invest? Thumbnail
ADD US ONG Google News

Precigen Shares on the Rise: Is Now the Time to Invest?

TIM SYKES•UPDATED AUG. 15, 2025, 9:19 AM ET
Reviewed by Bryce Tuohey Fact-checked by Matt Monaco

Precigen Inc. stocks have been trading up by 50.27 percent amid FDA designations fueling investor optimism.

Candlestick Chart

Live Update At 09:18:33 EST: On Friday, August 15, 2025 Precigen Inc. stock [NASDAQ: PGEN] is trending up by 50.27%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

A Look at Recent Financial Achievements

As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” Understanding this principle is crucial for traders looking to thrive in volatile markets. Focusing solely on profits can lead to risky decisions, so it’s important to prioritize strategies that protect your funds and ensure long-term sustainability in trading.

With lofty aspirations intertwined with financial realities, Precigen has faced its share of challenges. Its latest earnings report was a mixed bag. On one hand, revenues saw a slight slip compared to expectations. The company garnered $3.92M in revenue, a decline noticeable in their books when historical trends are analyzed. Yet, the company exhibited its financial resilience by effectively managing costs to boost liquidity.

Key financial metrics and ratios paint a clearer picture. Precigen’s EBIT margin sits at a low -3575.6%, highlighting the financial struggles of a growing biotech company trying to expand its development horizons. The enterprise value stands firm at $312.81M—a testament to its potential.

While profits remain elusive with a net loss clocking in at $26.64M, its current ratio of 2.7 suggests the firm possesses sufficient liquidity to meet its short-term obligations. Also, a quick ratio of 2.6 implies effective management in maintaining adequate cash flow. However, a price-to-sales ratio of 126.48 raises red flags about over-valuation, suggesting investor enthusiasm could be overinflated.

Market Sentiments and Trading Insights on PGEN Stock

Stock prices for Precigen have notably fluctuated as sentiments waver between optimism and skepticism. The intraday data reveals an opening price of $2.68, peaking to highs of $3.00 before closing at $2.92. Such impressive upward swings are symptomatic of anticipation surrounding its innovative prospects.

On a broader chart, the slightly meandering performance held its ground in late July, with dips and peaks reflecting market responses to company news. Despite a cavernous gap between low and high trades, the stock managed a firm clasp on investor interest, as emboldened by renewed industry buzz.

More Breaking News

Analysts’ ratings remain a mixed cocktail. While some are bullish, labeling it as a worthy buy, others caution against exuberance, urging a deliberative approach when considering investment decisions for potentially volatile equity like PGEN.

Breaking Down Key News Affecting Precigen

Technological Breakthroughs Trigger Emotions

Recent developments in Precigen’s research and development trajectory have sparked hope in its transformative potential. Investors’ bullish sentiments were driven by Precigen’s focus on gene therapies that, if successful, promise to catapult the company to new heights within the biotech sector.

Partnership Prospects Enthuse Investors

The exciting buzz around potential partnerships with major pharmaceutical giants has acted as a strong driving force. While these alliances remain speculative, possibilities of collaborations have elevated market enthusiasm, breathing life into stock performance.

Financial Performance: A Double-Edged Sword

Financially, Precigen’s performance indicates a paradox. Despite notable losses, an underlying ability to maintain a healthy cash flow demonstrates potential. However, this delicate balancing act leaves concerns about investor overvaluation, urging careful deliberation for traders gauging risks.

Are Investors’ Hopes Justified?

Precigen’s narrative is a multifaceted one—a blend of innovation, ambition, and market dynamics shaping its trajectory. A daring venture into Precigen is as exhilarating as it is risky. For seasoned enthusiasts, a deep dive into its fundamentals could make all the difference. Ultimately, Precigen’s fate rests in its inventive flair and strategic decisions. Traders eyeing promising payoffs must weigh potential rewards with palpable risks—navigating a landscape where precise timing and sagacious insights are crucial. As millionaire penny stock trader and teacher Tim Sykes emphasizes, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” In conclusion, eye the market closely, stay informed, and let discretion guide your trading choices in this thriving yet volatile biotech arena.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading PGEN

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”